Compare TG Therapeutics Inc (TGTX) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United States Oil ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while United States Oil ETF trades at $148.2 (market cap $1.90B). The key difference: TG Therapeutics Inc is far larger — about 4.3× United States Oil ETF's market cap, and United States Oil ETF is more actively traded (5,932,922 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and United States Oil ETF for 21 Days on average.
| TGTX | USO | |
|---|---|---|
Market Cap | $8.16B | $1.90B |
Volume | 1,735,121 | 5,932,922 |
Sector | Health | — |
52-Week High | $59.06 | $161.86 |
52-Week Low | $26.94 | $66.17 |
Typical Hold Time | 16 Days | 21 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
USO shows strong momentum with a 2.98% gain to $148.20, supported by bullish technical signals including positive moving averages and key resistance at $150. The oil sector faces mixed fundamentals with OPEC+ maintaining steady output while geopolitical tensions in the Middle East create supply uncertainty. Recent news highlights attacks on oil infrastructure and G-7 reserve releases impacting global oil markets.
The stock presents upside potential toward $152-154 resistance levels, though risks include oil price volatility from geopolitical events and potential supply disruptions. Investor sentiment remains cautiously optimistic given the technical strength, but fundamental clarity on earnings and margins is needed for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
